Avidity Partners Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Avidity Partners Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$932K	–	54
2026 Q1	$932K	Buy	+50,000	New	+$828K	0.19%	39
2025 Q3	–	Sell	-39,000	Closed	-$1.84M	–	55
2025 Q2	$1.84M	Buy	+39,000	New	+$1.59M	0.37%	49
2023 Q4	–	Sell	-777,172	Closed	-$44.3M	–	82
2023 Q3	$44.3M	Buy	777,172 +377,172	+94%	+$20.8M	1.78%	19
2023 Q2	$20.4M	Buy	+400,000	New	+$10.8M	0.71%	51
2022 Q2	–	Sell	-400,000	Closed	-$4.44M	–	92
2022 Q1	$4.44M	Hold	400,000	–	–	0.09%	76
2021 Q4	$3.96M	Hold	400,000	–	–	0.08%	85
2021 Q3	$3.94M	Hold	400,000	–	–	0.09%	91
2021 Q2	$4.14M	Hold	400,000	–	–	0.11%	98
2021 Q1	$4.08M	Hold	400,000	–	–	0.11%	87
2020 Q4	$4.55M	Buy	+400,000	New	+$4.25M	0.15%	83

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Avidity Partners Management's MLTX Position: Q2 2026 in Review

Avidity Partners Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2026, closing a stake of 50,000 shares — an estimated $932K sold.

Avidity Partners Management first reported a position in MLTX in Q4 2020 and held it in 10 quarters. The position peaked at $44.3M in Q3 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Avidity Partners Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2026 after selling out during the quarter.
Avidity Partners Management sold 50,000 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $932K.
Avidity Partners Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 10 quarters.
Avidity Partners Management's MoonLake Immunotherapeutics position peaked at $44.3M in Q3 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.